Polaris Collaborator to Present Research into ADI‑PEG 20’s Mechanism of Action at AACR 2009

Dr. Niramol Savaraj, Polaris collaborator and one of the principal investigators of the ongoing Phase 2 study of ADI‑PEG 20 in metastatic melanoma, will be presenting a poster at American Association for Cancer Research’s (AACR) 100th Annual Meeting, April 2009.

Advisory Panel Meeting Held in San Francisco: Plans for Phase 3 Trial of ADI‑PEG 20 in HCC Patients Discussed

Polaris, in collaboration with the Ludwig Institute for Cancer Research (LICR), held an Advisory Panel Meeting on January 15, 2009 in San Francisco. The meeting was held to discuss the design of a pivotal Phase 3 clinical trial of ADI‑PEG 20 in patients with hepatocellular carcinoma.

Polaris’ ADI‑PEG 20 Featured in Cancer Research Article: Novel Treatment for Prostate Cancer

The January 15th issue of Cancer Research highlighted an article on ADI‑PEG 20 by Polaris’ collaborators at the University of California, Davis.

Dr. Li-Tzong Chen to Present Results of Completed Asian Phase 2 Clinical Trial of ADI‑PEG 20 Treatment for HCC at ASCO Gastrointestinal Cancers Symposium

Polaris today announced Li-Tzong Chen, M.D. Ph.D., lead Principal Investigator of the recently completed Phase 2 study of ADI‑PEG 20 in advanced hepatocellular carcinoma, will be presenting a poster at the 2009 Gastrointestinal Cancers Symposium in San Francisco to report on the successful outcome of that study.

Polaris Acquires TDW Pharmaceuticals, Inc.

Polaris Group today announced that it has merged with TDW Pharmaceuticals, Inc. TDW Pharmaceuticals, Inc. is a Taiwan-based privately held biopharmaceutical company with subsidiaries in Shanghai, China and Northern California.

USPTO Issues Notice of Allowance for Polaris’ US Protein Kinase Inhibitors Patent

Polaris today announced that the United States Patent and Trademark Office has issued a notice of allowance for Polaris’ Protein Kinase Inhibitors patent application. This patent is for novel macrocyclic core derived compounds that inhibit protein kinases, including casein kinase 2 (CK2).

Press Conference Held in Taiwan to Announce the Results of a Phase 2 Trial of ADI‑PEG 20 in Advanced HCC

TDW Pharmaceuticals, Inc., an affiliate of Polaris in Taiwan, presented results from its sponsored trial of ADI‑PEG 20 in patients with hepatocellular carcinoma (HCC).

Polaris’ ADI‑PEG 20 Featured in International Journal of Cancer Article: Novel Treatment for Pancreatic Cancer

Polaris’ collaborators at the University of California, Davis have published an article on ADI‑PEG 20 in the October 15th issue of International Journal of Cancer.

Polaris Acquires Equity Stake in EnzymeRx

EnzymeRx announced that they have acquired worldwide rights, excluding Taiwan, to Uricase-PEG 20 from Polaris Pharmaceuticals, Inc. for 14 million dollars.

Ludwig Institute for Cancer Research Initiates Clinical Trial of Polaris’ ADI‑PEG 20 for the Treatment of Melanoma

Polaris today announced the enrollment of the first patient in a Phase I/II study using ADI‑PEG 20 to treat patients with advanced metastatic melanoma.